pilocarpine has been researched along with lenalidomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ashhab, MU; Gan, N; He, F; Kong, H; Omran, A; Peng, J; Yin, F | 1 |
1 review(s) available for pilocarpine and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for pilocarpine and lenalidomide
| Article | Year |
|---|---|
Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy.
Topics: Adolescent; Animals; Astrocytes; Case-Control Studies; Child; Epilepsy, Temporal Lobe; Female; Hippocampus; Humans; Lenalidomide; Lipopolysaccharides; Lithium Chloride; Male; MicroRNAs; Pilocarpine; Rats; Rats, Sprague-Dawley; Status Epilepticus; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |